Chile
Tuberculosis profile
Population  2013 18 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.22–0.22) 1.2 (1.2–1.3)
Mortality (HIV+TB only) <0.01 (<0.01–0.012) 0.03 (0.01–0.07)
Prevalence  (includes HIV+TB) 3.3 (1.3–6.3) 19 (7.5–36)
Incidence  (includes HIV+TB) 2.7 (2.6–3) 16 (14–17)
Incidence (HIV+TB only) 0.047 (0.045–0.11) 0.27 (0.25–0.63)
Case detection, all forms (%) 88 (80–94)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.7 (0.3–1.5) 4.5 (2–8.8)
MDR-TB cases among notified pulmonary
TB cases
12 (5–25) 10 (4–18)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 420   162
Pulmonary, clinically diagnosed 234   11
Extrapulmonary 560   25
       
Total new and relapse 2 412    
Previously treated, excluding relapses 38    
Total cases notified 2 450    
Among 2 412 new and relapse cases:
59 (2%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 180 (13%) 176 (75%) 427
Laboratory-confirmed RR-/MDR-TB cases     25
Patients started on MDR-TB treatment     14
TB/HIV 2013 Number (%)
TB patients with known HIV status 853 (35)
HIV-positive TB patients 187 (22)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 44
Previously treated cases, excluding relapse, registered in 2012 11
HIV-positive TB cases, all types, registered in 2012 40
RR-/MDR-TB cases started on second-line treatment in 2011 50
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 11.4
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 62%
% Funded internationally  
% Unfunded 38%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-05 Data: www.who.int/tb/data